Long-term functional outcomes after artificial urinary sphincter implantation in men with stress urinary incontinence

Priscilla Léon, Emmanuel Chartier-Kastler, Morgan Rouprêt, Vanina Ambrogi, Pierre Mozer, Véronique Phé

To cite this version:

HAL Id: hal-01103276
https://hal.sorbonne-universite.fr/hal-01103276
Submitted on 14 Jan 2015

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Long-term functional outcomes after artificial urinary sphincter (AMS 800®) implantation in men with stress urinary incontinence

Priscilla Léon¹ M.D, Emmanuel Chartier-Kastler¹ M.D, Ph.D, Morgan Rouprêt¹ M.D, Ph.D, Vanina Ambrogi² M.D, Pierre Mozer¹ M.D, Ph.D, Véronique Phé¹* M.D.

¹Pitié-Salpêtrière Academic Hospital, Department of Urology, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France

²Pitié-Salpêtrière Academic Hospital, Department of Statistics, Assistance Publique-Hôpitaux de Paris, Pierre and Marie Curie Medical School, Paris 6 University, Paris, France

**Running title:** Artificial urinary sphincter in men

**Keywords (MeSH):** Urinary incontinence; urinary sphincter; survival; outcomes

**Word count:** abstract (296); manuscript (2345)

*Corresponding author:

Véronique Phé, MD

Hôpital Pitié-Salpêtrière, Service d’urologie, 47-83 boulevard de l’hôpital, 75651 Paris Cedex 13, France

Phone: +33663231534; Email: veronique.phe@gmail.com
Abstract

Background. Artificial urinary sphincter (AUS) is the gold standard surgical treatment of male stress urinary incontinence (SUI) with sphincter deficiency since the 80’s.

Objective. To evaluate long-term functional outcomes of AUSs and to determine how many men required explantation because of SUI caused by sphincter deficiency after prostate surgery.

Design, setting and participants: Men who had undergone placement of an AMS 800® between 1984 and 1992 to relieve SUI caused by sphincter deficiency after prostate surgery were included.

Intervention. A peribulbar AUS was surgically inserted.

Outcome measurements and statistical analysis. Continence, defined as no need for pads, was assessed at the end of the follow up. Kaplan–Meier survival curves estimated the survival rate of the device without needing explantation or revision.

Results: Fifty-seven consecutive patients were included (median age 69 years; IQR: 64–72). Median duration of follow-up was 15 years (IQR: 8.25–19.75). At the end of follow-up, 25 patients (43.8%) still had their primary AUS. Explantation of an AUS was done in nine men because of erosion (n=7) and infection (n=2). Survival rates, without AUS explantation, were 87, 87, 80, and 80% at 5, 10, 15, and 20 years, respectively. Survival rates, without AUS revision, were 59, 28, 15, and 5% at 5, 10, 15, and 20 years, respectively. At the end of the follow-up, in intention-to-treat analysis, 77.2% of patients were continent.
**Conclusion:** In the long term (>10 years) the AMS 800® can offer a high rate of continence to men suffering from SUI caused by sphincter deficiency, with a tolerable rate of explantation and revision.

**Patient summary.** On the very long run (more than 10 years) AUS is able to offer high continence rate in men suffering from SUI after prostate surgery. The revision rate of the device increases with time.
Introduction

Artificial urinary sphincters (AUSs) have been used since 1972 for the treatment of urinary incontinence (UI) [1]. It has become the gold-standard treatment for males with UI caused by sphincter deficiency [2]. The AUS improves continence and quality of life [3]. The device has largely unchanged since its introduction by Scott et al.[1], and the number of AUSs implanted each year is increasing [4,5]. The AUS is supposed to have an average lifetime of 10 years [6,7]; however, few studies have reported on the longer-term (>10 years ) performance of AUSs [7,8]. The major postoperative complication of AUSs in the longer term is needing the device to be explanted because of erosion or infection. In addition, mechanical failure, which occurs in 2.0–13.8% of devices [9] leads to subsequent revision of the AUS.

Our goal was to report the functional results of AUSs implanted 20 years ago and to determine the mechanical-survival rate of the AMS800® in men suffering debilitating UI caused by sphincter deficiency after prostate surgery (retropubic radical prostatectomy, transurethral resection of the prostate, open prostatectomy).

Materials and methods

Population

Between 1984 and 1992, AUSs (AMS 800, American Medical Systems, Minnetonka, MN, USA) have been used to treat stress urinary incontinence (SUI) in non-neurogenic male patients in our department. The pre-implantation work-up comprised a clinical interview, analysis of voiding diaries (time and voided volumes, pad changes, incontinence episodes), a 1-hour pad test, a clinical examination, a cystoscopy and urodynamic assessment (cystomanometry and urethral-closure pressure).
**Surgery**

All patients had sterile urine at the time of surgery. Antibio-prophylaxis (amoxicillin-clavulanic acid) was given before surgery and was maintained until removal of the urethral catheter at day 2 after surgery. Surgery was performed by two experienced surgeons.

All patients were placed in the lithotomy position. After placing a 14-Fr urethral catheter, a median perineal incision was made. The bulbocavernosus muscles were separated and the bulbar urethra was isolated along 20 mm. The circumference of the urethra was measured, and then the cuff, which had been previously purged, was placed in position. The cuff tube was passed through the inguinal incision into the subcutaneous tissue. An inguinal incision was made on the side of the dominant hand of the patient. The front fascia of the rectus muscle was incised and a pre-peritoneal space was created to place the balloon, which was filled with 20 mL of isotonic product (the cuff had been previously pressurized and the balloon was inflated to 22 mL). The fascia was then closed. The pump was placed in the ipsilateral scrotum. Connections between the balloon and the pump, and between the cuff and the pump, were then carried out ensuring that air was absent from the system. Once the device had been tested, it was deactivated.

Perioperative and late surgical complications were reported according to Martin et al.’s criteria.[10] Early postoperative complications (<30 days) were recorded according to the Clavien–Dindo classification.[10] The device was activated after 6 weeks. Ease of activation was defined as immediate comprehension of the functioning of the device and the ability to manipulate it by the patient.

**Assessment of postoperative continence**
The patients were assessed at implantation, at AUS activation at 6 weeks post-surgery, and at follow-up visits at 3, 6, 12, 18, and 24 months after the procedure, and then annually. A clinical examination, pump manipulation, an X-ray examination, and post-voiding residual were assessed. Continence was defined as no need to use pads. Subjective satisfaction was assessed by asking the patient.

**Survival of the device**

Explantation and revision of the device were analyzed separately. Explantation was defined as complete removal of the proven or potentially infected AUS. Mechanical failure was defined as a fluid leak caused by rupture or perforation of any part, insufficient pressure, or reservoir migration. Non-mechanical problems were defined as cuff erosion and infection that led to explantation. The rates of explantation, revision, and deactivation were recorded.

**Statistical analyses**

Statistical analyses were performed using R (Free Software Foundation’s GNU project). The AUS survival rate without needing explantation (AUS in place and functioning) and the survival rate of the AUS without revision (AUS in place and functioning) were evaluated from the date of surgery to the last follow-up visit, using the Kaplan–Meier method. Univariate analyses used Cox’s model of proportional hazards (PROS PHREG) to determine the risk factors for explantation and revision. Hazard ratios were defined with a confidence interval of 95%. A p-value of <0.05 was considered statistically significant. The study was conducted after the patients’ written informed consent was obtained and the study was approved by the local ethics committee.
Results

Patients' characteristics

A total of 57 consecutive patients were included in this study. The median age of patients at the time of surgery was 69 years (IQR: 64–72). Median body-mass index was 25.3 (IQR: 23.9–27.6). The characteristics of the men enrolled are listed in Table 1. Among the 57 patients, 18 (31.6%) had undergone previous surgery for UI, six patients had received radiation therapy before implantation of an AUS, and one patient received an AUS because of prostate cancer. The median 1-h pad test-weight was 70 g (IQR: 38–100).

Surgery

Median surgical time was 85 min (IQR: 66–100). The characteristics of the implanted device are listed in Table 1.

Postoperative course

The median length of hospital stay after surgery was 6 days (IQR: 7–8.7). The AUS was activated 6 weeks later. All patients had easy activation of the device. Early postoperative complications are listed in Table 2. There were five minor complications (grade I–II) and one major complication (grade III–IV). No patient died during the postoperative course.

Clinical outcomes
At the end of the follow-up, 49 patients were still alive. Median follow-up time, including men with and without the device, was 15 years (IQR: 8.25–19.75). Figure 1 shows the outcomes of the AUSs for the 57 patients. No patient was lost to follow-up. Twenty-five patients (43.8%) still had their native AUS in place at the end of follow-up. Of the total patients, 47 (82.4%) had an activated AUS at the last follow-up.

**Deactivation.** At the last follow-up, four patients had a deactivated device because of dementia, erosion without an explantation, regular acute urinary retention caused by gross hematuria secondary to prostate cancer recurrence, and a massive stroke, making it impossible to use the device. One patient had deactivated the device, which allowed him to be continent.

**Continence.** At the last follow-up, in intention-to-treat analysis, 77.2% of patients were continent. The subjective satisfaction rate reported by patients at the last visit was 89.5%.

**Infections.** One infection occurred at 13 years after the initial implantation of the AUS and another infection occurred 3.5 years after.

**Erosion.** Incidences of erosion occurred at the median time of 6.25 years (IQR: 18 months–22 years). There were two peaks of occurrence: one within the first 4 years and the second at over 12 years. Overall, there were eight erosions. Erosion occurred after initial implantation of the AUS in five patients, after a revision of the AUS because of mechanical failure in 1 patient, after two revisions of the AUS in one patient, and after a third revision for one patient. One patient did not undergo explantation of his AUS (only deactivation) because of bad general-health condition.

**Explantation.** Explantation of the AUS was performed in nine patients because of erosion \((n = 7)\) or infection that caused erosion \((n = 2)\). The 5-, 10-, 15-, and 20-year survival rates without explantation of an AUS, with it in place and functioning, was 87%, 87%, 80%, and 80%, respectively (Figure 2). In univariate analyses, being aged >69 years, having a body-mass
index >25, prior radiation therapy, and the number of revisions were not significant risk factors for explantation.

**Revision.** The median number of revisions was one (IQR: 0–2). The 5-, 10-, 15-, and 20-year survival rates without revision of the AUS, while it was in place and functioning, was 59%, 28%, 15%, and 5%, respectively (Figure 3). In univariate analyses, being aged >69 years, a body-mass index >25, and prior radiation therapy were not significant risk factors for revision.

**Discussion**

To our knowledge, our study reports the longest follow-up of men implanted with an AUS. We found a continence rate of 77.2% at the last follow-up and, overall, the patients’ satisfaction was 89.5%. These results agree with rates reported by authors in studies that had 10-year periods of follow up [6,7]. AUS remains the gold-standard treatment for male UI caused by sphincter deficiency [2]; it has good functional outcomes and an acceptable morbidity. Table 3 summarizes the main functional outcomes for AUS in studies that have reported a >5-year follow-up [3,6,7,11–18].

As also reported in the literature, we found that overall satisfaction after implantation of an AUS was high, regardless of the presence of leaks or revisions [19]. The hospital stay 20 years ago was longer for this type of surgery, reflecting medical care at that time. It is important to note that the main indication for implanting of an AUS at that period was UI after benign prostate hyperplasia whereas, nowadays, radical prostatectomy is the main indication.

In our study, survival rate without explantation of an AUS at 5, 10, 15, and 20 years was 87%, 87%, 80%, and 80%, respectively, which is in line with previous reports [3,6,7,11–18]. The AUS is supposed to have an average lifetime of 10 years [6,7]. The major
postoperative complication of the AUS in the long term is the need for explantation of the device because of erosion or infection. Some papers have not reported erosion and infection separately; in our study, erosion rate was 14% and infection rate was 3.5%. In another study, pooled analysis of the mean rate of erosion and infection after implantation of an AUS in male non-neurogenic patients was 8.5% (range: 3.3–27.8%) [9].

Infection and erosion generally occur within 2 years after implantation, although much later cases have been reported [20]. It is not clear whether coating the device diminishes erosion and infection rates. The AMS 800® device is now available in some countries with a rifampicin and minocycline coating on the cuff and pump components, but not on the pressure-regulating balloon and its tubing. Surgical experience is also probably of great importance in preventing early infection and erosion. Sandhu et al. recently suggested that the learning curve for this kind of surgery does not reach a plateau, even after >200 surgical procedures [21]. Walsh et al. reported an increased risk of infection and erosion in patients that had undergone irradiation. However, placement of a urethral catheter without due consideration of the AUS cuff may also account for cases of late erosion [22]. The putative increased risk of erosion with prior or subsequent radiotherapy has never been proven in well-designed and powered cohort studies using homogeneous patient populations. In our study, radiotherapy was not identified as a significant risk factor for explantation or revision, contrary to previous reports [13,23].

We reported an intention-to-treat revision rate of 40.3%. Furthermore, the 5-, 10-, 15-, and 20-year survival rates of the AUs without needing revision, and while it was still in place and functioning, dramatically decreased with time. Mechanical failure-rates varied between 2.0% and 13.8%, with failures reported from 11 months to 68.1 months postinsertion [9]. Due to the retrospective nature of this study, the mechanical-failure rate might be underestimated.
However, global reintervention rate provides an overview of complications that occur following AUS implantation and the need invasive treatment: these should be regarded as an important end-point for comparisons with other surgical alternatives.

In a pooled analysis of 549 patients (10 studies) with non-neurogenic SUI, the mean reintervention rate was computed as 26.0% (range: 14.8–44.8%) [9]; in addition, the timing of re-interventions was mainly influenced by the underlying cause. The patients needed a mean of 1.5 re-interventions. This result is in accordance with our study, where any recurrence of urinary leakage was attributed to urethral atrophy. Urethral atrophy is a well-known late complication after implantation of an AUS, and is typically presumed when recurrence of SUI occurs during follow-up with a functioning AUS [11,19,24,25]. Urethral-tissue hypoxia has been suggested to be the main pathophysiologic mechanism [26].

Determining the rate of urethral atrophy is a complex issue because it is potentially influenced by follow-up duration, device pressure, implantation technique, and the patient's characteristics. In the only prospective study, reported by Trigo Rocha et al., two patients developed urethral atrophy after a mean of 29.4 months [24]. A history of radiation therapy has been proposed as a risk factor for urethral atrophy. However, current knowledge on urethral atrophy in non-neurogenic patients remains limited and is based on weak retrospective data.

Consequently, despite favorable outcomes and satisfaction rates after implantation, the AUS continues to be associated with the risk of local complications (i.e., atrophy, erosion, and infection) or mechanical failure. Thus, regular revisions and/or explantations are mandatory in at least 30% of AUS devices. New and more sophisticated AUS devices have been recently developed to improve function, occlusive efficiency, and biocompatibility relative to the AUS's current design [27]. The present study also underlines the necessity of only implanting
an AUS in cognitively and motor-“valid” patients: our population included one case of dementia and one case of brain stroke. These health issues were directly responsible for the patients’ inability to handle the pump, which led to needing to deactivate the AUS and a relapse of incontinence.

New AUS devices are awaited to decrease the incidence of mechanical failure and to improve urethral protection [27]. Alternatively, slings or adjustable continence therapies (proACT®) may be of great interest as there is no device, as yet, able to manipulate voidance. However, these may create some degree of obstruction and more long-term follow-up studies are needed [2].

**Conclusion**

The AUS provided satisfactory long-term functional results for more than 10 years among men with SUI caused by sphincter deficiency. Not surprisingly, the device needed revision between 5 and 10 years. However, it is worth noting that >70% of the men remained continent in the long run.

**References**


**Figure captions**

**Figure 1.** Flowchart showing the outcomes of 57 implanted artificial urinary sphincters.

**Figure 2.** Explantation-free survival curve for men implanted with an artificial urinary sphincter.

**Figure 3.** Revision-free survival curve for men implanted with an artificial urinary sphincter.

**Tables**

**Table 1.** Characteristics of the patients and of the implanted artificial urinary sphincters.

**Table 2.** Early postoperative complications according to the Clavien–Dindo classification.

**Table 3.** Main outcomes of artificial urinary sphincters over a 5-year follow-up period taken from the literature.
Take Home Message

The AUS provided satisfactory long-term functional results for more than 10 years among men with SUI caused by sphincter deficiency with >70% of the men remaining continent. Not surprisingly, the device needed revision between 5 and 10 years.
Fig 1. Flowchart showing the outcomes of 57 implanted artificial urinary sphincters.

57 patients with an AUS
- 8 patients deceased
- 49 patients alive
  - 20 native AUS
    - 16 activated
      - 1 dementia
      - 1 prostate cancer with gross hematuria and acute urinary retention
    - 1 deactivated but efficient
      - 3 deactivated
        - 1 erosion, not explanted because of bad health condition
  - 23 revised AUS and activated
    - 15 had 1 revision
      - 4 had 2 revisions
    - 4 had 2 revisions
    - 2 had 3 revisions
    - 2 had 4 revisions
  - 6 explantations
    - 2 infections
      - 4 erosions: among these, 2 re-implantations
    - 3 explantations for erosions: among these 2 re-implantations
Explantation-free survival curve for the men implanted with an AUS (confidence intervals are mentioned in dashed curves).
Revision-free survival curves for the men implanted with an AUS (confidence intervals are mentioned in dashed curves).
Table 1. Characteristics of patients and of the implanted artificial urinary sphincters

<table>
<thead>
<tr>
<th>N= 57 patients</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type of prostate surgery leading to urinary incontinence</td>
<td></td>
</tr>
<tr>
<td>Retropubic radical prostatectomy</td>
<td>6 (10.5 %)</td>
</tr>
<tr>
<td>Open prostatectomy</td>
<td>16 (28.1%)</td>
</tr>
<tr>
<td>Transurethral resection of the prostate (TURP)</td>
<td>35 (61.4%)</td>
</tr>
<tr>
<td>No of previous surgery for urinary incontinence</td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>39 (68.4%)</td>
</tr>
<tr>
<td>1</td>
<td>11 (19.3%)</td>
</tr>
<tr>
<td>2</td>
<td>4 (7%)</td>
</tr>
<tr>
<td>3</td>
<td>2 (3.5%)</td>
</tr>
<tr>
<td>≥4</td>
<td>1 (1.8%)</td>
</tr>
<tr>
<td>AUS cuff size</td>
<td></td>
</tr>
<tr>
<td>4 cm</td>
<td>1 (1.8%)</td>
</tr>
<tr>
<td>4,5 cm</td>
<td>44 (77.2%)</td>
</tr>
<tr>
<td>5 cm</td>
<td>5 (8.8%)</td>
</tr>
<tr>
<td>5,5 cm</td>
<td>5 (8.8%)</td>
</tr>
<tr>
<td>6,5 cm</td>
<td>2 (3.6%)</td>
</tr>
<tr>
<td>Balloon size</td>
<td></td>
</tr>
<tr>
<td>51-60 cmH2O</td>
<td>31 (54.3%)</td>
</tr>
<tr>
<td>61-70 cmH2O</td>
<td>26 (45.7%)</td>
</tr>
<tr>
<td>Pump location</td>
<td></td>
</tr>
<tr>
<td>Right</td>
<td>44 (77.2%)</td>
</tr>
<tr>
<td>Left</td>
<td>13 (22.8%)</td>
</tr>
</tbody>
</table>
### Table 2. Early postoperative complications according to Clavien-Dindo Classification

<table>
<thead>
<tr>
<th>Clavien-Dindo grading system</th>
<th>n=</th>
<th>type</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>1</td>
<td>Scrotal edema</td>
<td>analgesic</td>
</tr>
<tr>
<td>II</td>
<td>4</td>
<td>1 urinary tract infection</td>
<td>antibiotic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2 orchi-epididymitis</td>
<td>antibiotic</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 acute urinary retention</td>
<td>bladder catheterization</td>
</tr>
<tr>
<td>IIIa</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IIIb</td>
<td>1</td>
<td>Immediate post operative hematoma</td>
<td>Evacuation in the operating room</td>
</tr>
<tr>
<td>IV</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>V</td>
<td>0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>6</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 3. Main outcomes of artificial urinary sphincters over a 5-year follow-up period taken from the literature.

<table>
<thead>
<tr>
<th>References</th>
<th>N=</th>
<th>Mean age</th>
<th>Mean follow up (yrs)</th>
<th>% continence</th>
<th>% infection</th>
<th>% erosion</th>
<th>% urethral atrophy</th>
<th>% surgical intervention</th>
<th>AUS durability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elliot et al. [11]</td>
<td>184/323 narrow backing cuff 139/323 pre narrow backing cuff</td>
<td>60.4</td>
<td>5.7</td>
<td>nr</td>
<td>0.5/3</td>
<td>6.5/6.0</td>
<td>nr</td>
<td>17.0/42.0</td>
<td>75% at 5 yrs 67% at 5 yrs</td>
</tr>
<tr>
<td>Venn et al. [8]</td>
<td>100 with 70 men</td>
<td>35</td>
<td>11</td>
<td>84</td>
<td>37/23</td>
<td>nr</td>
<td>60</td>
<td></td>
<td>Male bulbar urethral cuff: original device 52% at 10 yrs 71% at 5 yrs</td>
</tr>
<tr>
<td>Gousse et al. [12]</td>
<td>71/131</td>
<td>72</td>
<td>7.7</td>
<td>59</td>
<td>1.4/4.2</td>
<td>nr</td>
<td>29.6</td>
<td></td>
<td>79.4% at 5 yrs (native AUS) 88% at 5yrs (revised AUS)</td>
</tr>
<tr>
<td>Raj et al. [13]</td>
<td>554</td>
<td>68</td>
<td>&gt;4.2</td>
<td>88.5</td>
<td>0.5/5.2</td>
<td>14.0</td>
<td>19.1</td>
<td></td>
<td>79% at 5 yrs</td>
</tr>
<tr>
<td>Montague et al. [14]</td>
<td>209</td>
<td>68</td>
<td>5.1</td>
<td>64</td>
<td>nr/6</td>
<td>6.6</td>
<td>12</td>
<td></td>
<td>88% at 5 yrs</td>
</tr>
<tr>
<td>Haab et al. [3]</td>
<td>68</td>
<td>68</td>
<td>7.2</td>
<td>80</td>
<td>nr/2.9</td>
<td>8.8</td>
<td>25</td>
<td></td>
<td>70% at 7 yrs (25% revised and 5.8% explanted)</td>
</tr>
<tr>
<td>Fulford el al. [7]</td>
<td>61/68 with 43 men</td>
<td>26</td>
<td>10</td>
<td>61</td>
<td>nr/31</td>
<td>nr</td>
<td>80.3</td>
<td></td>
<td>75% at 10 yrs</td>
</tr>
<tr>
<td>Kim et al. [15]</td>
<td>124</td>
<td>65.9</td>
<td>6.8</td>
<td>82</td>
<td>5.64/8.06</td>
<td>nr</td>
<td>37</td>
<td></td>
<td>64% at 10 yrs</td>
</tr>
<tr>
<td>Petero et al. [16]</td>
<td>108, among them 53 men</td>
<td>63.1</td>
<td>8.1</td>
<td>62</td>
<td>1.14 men 1.25 women</td>
<td>15.9 men 6.25 women</td>
<td>nr</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Gulpinar et al. [17]</td>
<td>56</td>
<td>61.8</td>
<td>8</td>
<td>46</td>
<td>7.1/8.9</td>
<td>nr</td>
<td>41.1</td>
<td></td>
<td>50 at 3 yrs 45% at 10 yrs</td>
</tr>
<tr>
<td>Bordenave et al. [18]</td>
<td>159</td>
<td>68.4</td>
<td>5.75</td>
<td>74.2</td>
<td>4.4/4.5</td>
<td>7.5</td>
<td>32.4</td>
<td></td>
<td>86.2 at 6yrs</td>
</tr>
<tr>
<td>Present series</td>
<td>57</td>
<td>69</td>
<td>15</td>
<td>77.19</td>
<td>3.51/17.5</td>
<td>0</td>
<td>64.2</td>
<td></td>
<td>87% at 5 and 10 yrs 80% at 15 and 20 yrs</td>
</tr>
</tbody>
</table>

NR: not reported